Importance: Fluid therapy is an important component of care for patients with traumatic brain injury, but whether it modulates clinical outcomes remains unclear. Objective: To determine whether continuous infusion of hypertonic saline solution improves neurological outcome at 6 months in patients with traumatic brain injury. Design, Setting, and Participants: Multicenter randomized clinical trial conducted in 9 intensive care units in France, including 370 patients with moderate to severe traumatic brain injury who were recruited from October 2017 to August 2019. Follow-up was completed in February 2020. Interventions: Adult patients with moderate to severe traumatic brain injury were randomly assigned to receive continuous infusion of 20% hypertonic saline solution plus standard care (n = 185) or standard care alone (controls; n = 185). The 20% hypertonic saline solution was administered for 48 hours or longer if patients remained at risk of intracranial hypertension. Main Outcomes and Measures: The primary outcome was Extended Glasgow Outcome Scale (GOS-E) score (range, 1-8, with lower scores indicating worse functional outcome) at 6 months, obtained centrally by blinded assessors and analyzed with ordinal logistic regression adjusted for prespecified prognostic factors (with a common odds ratio [OR] >1.0 favoring intervention). There were 12 secondary outcomes measured at multiple time points, including development of intracranial hypertension and 6-month mortality. Results: Among 370 patients who were randomized (median age, 44 [interquartile range, 27-59] years; 77 [20.2%] women), 359 (97%) completed the trial. The adjusted common OR for the GOS-E score at 6 months was 1.02 (95% CI, 0.71-1.47; P = .92). Of the 12 secondary outcomes, 10 were not significantly different. Intracranial hypertension developed in 62 (33.7%) patients in the intervention group and 66 (36.3%) patients in the control group (absolute difference, -2.6% [95% CI, -12.3% to 7.2%]; OR, 0.80 [95% CI, 0.51-1.26]). There was no significant difference in 6-month mortality (29 [15.9%] in the intervention group vs 37 [20.8%] in the control group; absolute difference, -4.9% [95% CI, -12.8% to 3.1%]; hazard ratio, 0.79 [95% CI, 0.48-1.28]). Conclusions and Relevance: Among patients with moderate to severe traumatic brain injury, treatment with continuous infusion of 20% hypertonic saline compared with standard care did not result in a significantly better neurological status at 6 months. However, confidence intervals for the findings were wide, and the study may have had limited power to detect a clinically important difference. Trial Registration: ClinicalTrials.gov Identifier: NCT03143751.
Importance: Fluid therapy is an important component of care for patients with traumatic brain injury, but whether it modulates clinical outcomes remains unclear. Objective: To determine whether continuous infusion of hypertonic saline solution improves neurological outcome at 6 months in patients with traumatic brain injury. Design, Setting, and Participants: Multicenter randomized clinical trial conducted in 9 intensive care units in France, including 370 patients with moderate to severe traumatic brain injury who were recruited from October 2017 to August 2019. Follow-up was completed in February 2020. Interventions: Adult patients with moderate to severe traumatic brain injury were randomly assigned to receive continuous infusion of 20% hypertonic saline solution plus standard care (n = 185) or standard care alone (controls; n = 185). The 20% hypertonic saline solution was administered for 48 hours or longer if patients remained at risk of intracranial hypertension. Main Outcomes and Measures: The primary outcome was Extended Glasgow Outcome Scale (GOS-E) score (range, 1-8, with lower scores indicating worse functional outcome) at 6 months, obtained centrally by blinded assessors and analyzed with ordinal logistic regression adjusted for prespecified prognostic factors (with a common odds ratio [OR] >1.0 favoring intervention). There were 12 secondary outcomes measured at multiple time points, including development of intracranial hypertension and 6-month mortality. Results: Among 370 patients who were randomized (median age, 44 [interquartile range, 27-59] years; 77 [20.2%] women), 359 (97%) completed the trial. The adjusted common OR for the GOS-E score at 6 months was 1.02 (95% CI, 0.71-1.47; P = .92). Of the 12 secondary outcomes, 10 were not significantly different. Intracranial hypertension developed in 62 (33.7%) patients in the intervention group and 66 (36.3%) patients in the control group (absolute difference, -2.6% [95% CI, -12.3% to 7.2%]; OR, 0.80 [95% CI, 0.51-1.26]). There was no significant difference in 6-month mortality (29 [15.9%] in the intervention group vs 37 [20.8%] in the control group; absolute difference, -4.9% [95% CI, -12.8% to 3.1%]; hazard ratio, 0.79 [95% CI, 0.48-1.28]). Conclusions and Relevance: Among patients with moderate to severe traumatic brain injury, treatment with continuous infusion of 20% hypertonic saline compared with standard care did not result in a significantly better neurological status at 6 months. However, confidence intervals for the findings were wide, and the study may have had limited power to detect a clinically important difference. Trial Registration: ClinicalTrials.gov Identifier: NCT03143751.
Authors: Peter J Hutchinson; Angelos G Kolias; Ivan S Timofeev; Elizabeth A Corteen; Marek Czosnyka; Jake Timothy; Ian Anderson; Diederik O Bulters; Antonio Belli; C Andrew Eynon; John Wadley; A David Mendelow; Patrick M Mitchell; Mark H Wilson; Giles Critchley; Juan Sahuquillo; Andreas Unterberg; Franco Servadei; Graham M Teasdale; John D Pickard; David K Menon; Gordon D Murray; Peter J Kirkpatrick Journal: N Engl J Med Date: 2016-09-07 Impact factor: 91.245
Authors: Andrew I R Maas; Ewout W Steyerberg; Anthony Marmarou; Gillian S McHugh; Hester F Lingsma; Isabella Butcher; Juan Lu; James Weir; Bob Roozenbeek; Gordon D Murray Journal: Neurotherapeutics Date: 2010-01 Impact factor: 7.620
Authors: Ewout W Steyerberg; Eveline Wiegers; Charlie Sewalt; Andras Buki; Giuseppe Citerio; Véronique De Keyser; Ari Ercole; Kevin Kunzmann; Linda Lanyon; Fiona Lecky; Hester Lingsma; Geoffrey Manley; David Nelson; Wilco Peul; Nino Stocchetti; Nicole von Steinbüchel; Thijs Vande Vyvere; Jan Verheyden; Lindsay Wilson; Andrew I R Maas; David K Menon Journal: Lancet Neurol Date: 2019-10 Impact factor: 44.182
Authors: Ewout W Steyerberg; Nino Mushkudiani; Pablo Perel; Isabella Butcher; Juan Lu; Gillian S McHugh; Gordon D Murray; Anthony Marmarou; Ian Roberts; J Dik F Habbema; Andrew I R Maas Journal: PLoS Med Date: 2008-08-05 Impact factor: 11.069
Authors: Geert Meyfroidt; Pierre Bouzat; Michael P Casaer; Randall Chesnut; Sophie Rym Hamada; Raimund Helbok; Peter Hutchinson; Andrew I R Maas; Geoffrey Manley; David K Menon; Virginia F J Newcombe; Mauro Oddo; Chiara Robba; Lori Shutter; Martin Smith; Ewout W Steyerberg; Nino Stocchetti; Fabio Silvio Taccone; Lindsay Wilson; Elisa R Zanier; Giuseppe Citerio Journal: Intensive Care Med Date: 2022-05-20 Impact factor: 41.787
Authors: Seif Tarek El-Swaify; Mazen A Refaat; Sara H Ali; Abdelrahman E Mostafa Abdelrazek; Pavly Wagih Beshay; Menna Kamel; Bassem Bahaa; Abdelrahman Amir; Ahmed Kamel Basha Journal: Trauma Surg Acute Care Open Date: 2022-01-05
Authors: Melinda Fitzgerald; Jennie Ponsford; Natasha A Lannin; Terence J O'Brien; Peter Cameron; D James Cooper; Nick Rushworth; Belinda Gabbe Journal: Neurotrauma Rep Date: 2022-06-07
Authors: Alexis F Turgeon; Dean A Fergusson; Lucy Clayton; Marie-Pier Patton; Ryan Zarychanski; Shane English; Annemarie Docherty; Timothy Walsh; Donald Griesdale; Andreas H Kramer; Damon Scales; Karen E A Burns; John Gordon Boyd; John C Marshall; Demetrios J Kutsogiannis; Ian Ball; Paul C Hébert; Francois Lamontagne; Olivier Costerousse; Maude St-Onge; Paule Lessard Bonaventure; Lynne Moore; Xavier Neveu; Andrea Rigamonti; Kosar Khwaja; Robert S Green; Vincent Laroche; Alison Fox-Robichaud; Francois Lauzier Journal: BMJ Open Date: 2022-10-10 Impact factor: 3.006